Kodiak Sciences Beats Q2 Loss Estimates
Kodiak Sciences (NASDAQ:KOD), a biotechnology company specializing in retinal disease therapies, released its Q2 2025 earnings results on August 13, 2025. The most notable news: the company reported a GAAP net loss of $54.3 million, translating to a GAAP EPS loss of $(1.03), beating consensus estimates of $(1.07) by $0.04 (GAAP). No product revenue was reported or expected, as Kodiak remains pre-commercial. Rising research and development (R) spending fueled clinical trial progress, but cash burn accelerated, with cash and cash equivalents decreasing from $138.9 million at March 31, 2025, to $104.2 million at June 30, 2025. Results point to a company in the critical late-stages of clinical development, with cash resources projected to last into 2026 as it moves toward key data readouts in its major programs.
Source: Analyst estimates for the quarter provided by FactSet.
Kodiak Sciences is a biotechnology firm focused on developing new drugs for diseases that affect the retina, the light-sensing tissue at the back of the eye. Its approach relies on a proprietary platform for designing antibody-based treatments. The company’s business remains pre-commercial: its medicines generate no revenue yet, as they are still in clinical studies.
Source Fool.com
